RGC net incomeFY2026-$11.70M
RGC net income was -$11.70M for fiscal 2026 (ended Jun 30, 2026), compared with -$3.58M in fiscal 2025.
Regencell Bioscience Holdings Limited (RGC) financials
For fiscal 2026 (ended Jun 30, 2026), Regencell Bioscience Holdings Limited reported -$11.70M of net income.
- Net income, FY2026
- -$11.70M
- EPS, diluted, FY2026
- -$2.37
- Cash
- $14.19M
- Market cap
- $2.61B
FY2019FY2026
FY2020FY2025
RGC revenue and earnings growth
RGC EPSFY2026-$2.37
RGC diluted EPS was -$2.37 for fiscal 2026 (ended Jun 30, 2026), compared with -$0.72 in fiscal 2025.
RGC free cash flowFY2025-$3.27M
RGC free cash flow was -$3.27M for fiscal 2025 (ended Jun 30, 2025), compared with -$4.01M in fiscal 2024.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $1.30M | $948.3K | $1.07M | $1.58M | $2.51M | $438.3K | $386.2K | $228.2K |
| Selling, general and admin | $10.42M | $2.81M | $3.55M | $4.43M | $5.08M | $941.5K | $311.9K | $159.1K |
| Operating income | -$11.72M | -$3.77M | -$4.74M | -$6.27M | -$7.62M | -$1.38M | -$812.4K | -$391.0K |
| Pre-tax income | -$11.70M | -$3.58M | -$4.36M | -$6.06M | -$7.59M | -$1.35M | -$812.4K | -$391.0K |
| Net income | -$11.70M | -$3.58M | -$4.30M | -$5.87M | -$7.45M | -$1.35M | $812.4K | -$391.0K |
| EPS, basic | -$2.37 | -$0.72 | -$0.87 | -$1.19 | -$0.58 | $0.13 | $0.08 | - |
| EPS, diluted | -$2.37 | -$0.72 | -$0.87 | -$1.19 | -$0.58 | -$0.13 | -$0.08 | - |
| Diluted shares | 494.6M | 494.5M | 494.5M | 494.5M | 12.8M | 10.0M | 10.0M | 10.0M |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.19M | $2.42M | $2.96M | $1.56M | $6.42M | $59.4K | $387.0K | $243.3K |
| Short-term investments | - | $2.48M | $5.00M | $10.00M | $10.00M | - | - | - |
| Current assets | $14.22M | $4.90M | $8.11M | $11.62M | $16.44M | $66.8K | $387.0K | - |
| Total assets | $14.73M | $5.76M | $8.44M | $12.62M | $18.02M | $340.1K | $514.0K | - |
| Current liabilities | $1.32M | $663.7K | $193.6K | $606.9K | $577.8K | $4.34M | $3.16M | - |
| Total liabilities | $1.38M | $895.3K | $219.5K | $632.3K | $938.0K | $4.34M | $3.16M | - |
| Shareholders' equity | $13.35M | $4.86M | $8.22M | $11.99M | $17.08M | -$4.00M | -$2.65M | -$1.84M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.70M | -$3.11M | -$4.00M | -$4.96M | -$5.27M | -$767.3K | -$726.6K | -$391.0K |
| Capital expenditures | - | $152.7K | $5.4K | $27.4K | $780.9K | - | $117.8K | - |
| Free cash flow | - | -$3.27M | -$4.01M | -$4.99M | -$6.05M | - | -$844.4K | - |
| Investing cash flow | $2.50M | $2.69M | $5.24M | $59.0K | -$10.78M | - | -$117.8K | - |
| Financing cash flow | $16.95M | - | $102.3K | $134.9K | $22.41M | $439.7K | $988.1K | $481.0K |
| Stock-based compensation | $3.23M | $244.8K | $449.3K | $922.6K | $2.76M | - | - | - |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 |
|---|---|---|---|---|---|---|---|---|
| Return on equity | -87.7% | -73.7% | -52.3% | -49.0% | -43.6% | - | - | - |
| Return on assets | -79.4% | -62.3% | -51.0% | -46.5% | -41.3% | -395.9% | 158.0% | - |
| Current ratio | 10.77 | 7.39 | 41.92 | 19.15 | 28.46 | 0.02 | 0.12 | - |
Source: XBRL data Regencell Bioscience Holdings Limited files with the SEC, latest filing dated Oct 7, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
RGC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| RGC | - | - | -$11.70M | - | $2.61B |
| PM | $43.14B | +7.9% | $10.71B | 24.8% | $308.43B |
| BTI | £25.61B | -1.0% | £7.76B | 30.3% | $131.54B |
| MO | $23.52B | +0.5% | $8.12B | 34.5% | $126.62B |
| DFTX | - | - | -$353.79M | - | $4.47B |
| TRLV | $1.08B | -9.1% | -$445.60M | -41.2% | $2.23B |
| RLX | CN¥3.96B | +44.0% | CN¥921.87M | 23.3% | $1.97B |
| CRON | $271.85M | +54.3% | $63.36M | 23.3% | $1.33B |
| TLRY | $963.10M | +15.9% | -$164.22M | -17.1% | $430.8M |
RGC FAQ
5 questionsIs RGC profitable?
No. Regencell Bioscience Holdings Limited reported a net loss of $11.70M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does RGC have?
Regencell Bioscience Holdings Limited reported $14.19M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is RGC earnings per share?
Diluted earnings per share were -$2.37 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did RGC last report financial results?
The latest statements here come from Regencell Bioscience Holdings Limited's 20-F filed on Oct 7, 2026, covering the period ended Jun 30, 2026.Where does this RGC financial data come from?
Quantisnow builds these statements from the structured XBRL data Regencell Bioscience Holdings Limited files with the SEC. It is provided for information only and is not investment advice.